Applied Health Economics and Health Policy

2008 - 2025

Current editor(s): Timothy Wrightson

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 11, issue 6, 2013

An Overview of the Health Economic Implications of Elective Caesarean Section pp. 561-576

Stavros Petrou and Kamran Khan

The Economic Burden of Complications Occurring in Major Surgical Procedures: a Systematic Review pp. 577-592

Ajay Patel, Annika Bergman, Brigitte Moore and Ulf Haglund

Cost-Effectiveness Analyses of Osteoarthritis Oral Therapies: a Systematic Review pp. 593-618

Ronald Wielage, Julie Myers, Robert Klein and Michael Happich

Are the True Impacts of Adverse Events Considered in Economic Models of Antineoplastic Drugs? A Systematic Review pp. 619-637

Alison Pearce, Marion Haas and Rosalie Viney

Preferences on Policy Options for Ensuring the Financial Sustainability of Health Care Services in the Future: Results of a Stakeholder Survey pp. 639-652

David Tordrup, Aris Angelis and Panos Kanavos

Incremental Cost Effectiveness of Pharmacist-Managed Erythropoiesis-Stimulating Agent Clinics for Non-Dialysis-Dependent Chronic Kidney Disease Patients pp. 653-660

Sherrie Aspinall, Kenneth Smith, Chester Good, Xinhua Zhao, Roslyn Stone, Ivy Tonnu-Mihara and Francesca Cunningham

A Model-Based Economic Evaluation of Improved Primary Care Management of Patients with Type 2 Diabetes in Australia pp. 661-670

Hossein Haji Ali Afzali, Jodi Gray, Justin Beilby, Christine Holton and Jonathan Karnon

Direct Medical Cost and Glycemic Control in Type 2 Diabetic Saudi Patients pp. 671-675

Nora Almutairi and Khalid Alkharfy

Impact of Delisting ARBs, Apart from Losartan, on ARB Utilisation Patterns in Denmark: Implications for Other Countries pp. 677-685

Ulrik Hesse, Brian Godman, Max Petzold, Andrew Martin and Rickard Malmström

Erratum to: Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland pp. 687-687

Dawn Lee, Patrick Thornton, Alexander Hirst, Lucie Kutikova, Robert Deuson and Nic Brereton

Erratum to: Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany pp. 689-689

Jan Zeidler, Jörg Mahlich, Wolfgang Greiner and Stephan Heres

Volume 11, issue 5, 2013

Generic Medicines: Solutions for a Sustainable Drug Market? pp. 437-443

Pieter Dylst, Arnold Vulto, Brian Godman and Steven Simoens

Systematic Review of Drug Administration Costs and Implications for Biopharmaceutical Manufacturing pp. 445-456

Ebenezer Tetteh and Stephen Morris

Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland pp. 457-469

Dawn Lee, Patrick Thornton, Alexander Hirst, Lucie Kutikova, Robert Deuson and Nic Brereton

Does the Type of Provider and the Place of Residence Matter in the Utilization of Prenatal Ultrasonography? Evidence from Canada pp. 471-484

Harminder Guliani, Ardeshir Sepehri and John Serieux

Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US pp. 485-497

Anju Parthan, Morgan Kruse, Nicole Yurgin, Joice Huang, Hema Viswanathan and Douglas Taylor

Preferences for Colorectal Cancer Screening Techniques and Intention to Attend: a Multi-Criteria Decision Analysis pp. 499-507

J. Hummel, Lotte Steuten, C. Groothuis-Oudshoorn, Nick Mulder and Maarten IJzerman

Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany pp. 509-521

Jan Zeidler, Jörg Mahlich, Wolfgang Greiner and Stephan Heres

Private Expenditures on Brand Name Prescription Drugs after Generic Entry pp. 523-529

Dahlia Balaban, Irfan Dhalla, Michael Law and Chaim Bell

Economic Evaluation of Cardio inCode ®, a Clinical-Genetic Function for Coronary Heart Disease Risk Assessment pp. 531-542

A. Ramírez de Arellano, A. Coca, M. de la Figuera, C. Rubio-Terrés, D. Rubio-Rodríguez, A. Gracia, A. Boldeanu, J. Puig-Gilberte and E. Salas

Evolutions in Both Co-Payment and Generic Market Share for Common Medication in the Belgian Reference Pricing System pp. 543-552

Jessica Fraeyman, Moira Verbelen, Niel Hens, Guido Hal, Hans Loof and Philippe Beutels

Comment on: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective” pp. 553-554

Hiltrud Liedgens and Rainer Henske

Authors’ Reply to Liedgens and Henske: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective” pp. 555-557

Ronald Wielage, Megha Bansal, J. Andrews, Robert Klein and Michael Happich

Volume 11, issue 4, 2013

New Anti-Rebate Legislation in South Korea pp. 311-318

Su-Yeon Yu, Bong-Min Yang and Jin-Hyun Kim

Quantifying Benefit–Risk Preferences for Medical Interventions: An Overview of a Growing Empirical Literature pp. 319-329

A. Brett Hauber, Angelyn Fairchild and F. Reed Johnson

Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis pp. 331-341

Annie Hawton, James Shearer, Elizabeth Goodwin and Colin Green

A Practical Approach for Calculating Reliable Cost Estimates from Observational Data: Application to Cost Analyses in Maternal and Child Health pp. 343-357

Jason Salemi, Meg Comins, Kristen Chandler, Mulubrhan Mogos and Hamisu Salihu

The Trade-off Between Costs and Quality of Care in the Treatment of Psychosomatic Patients with Somatoform Pain Disorder pp. 359-368

Laura Haas, Tom Stargardt, Jonas Schreyoegg, Rico Schlösser, Burghard Klapp and Gerhard Danzer

The Role of Financial Wellbeing, Sociopolitical Attitude, Self-Interest, and Lifestyle in One’s Attitude Toward Social Health Insurance pp. 369-381

Oliver Schnusenberg, Chung-Ping Loh and Katrin Nihalani

Changes in the Utilization of Venlafaxine after the Introduction of Generics in Sweden pp. 383-393

Brian Godman, Marie Persson, Jamilette Miranda, Peter Skiöld, Björn Wettermark, Corrado Barbui and Lars Gustafsson

Compliance with Pharmacotherapy and Direct Healthcare Costs in Patients with Parkinson’s Disease: A Retrospective Claims Database Analysis pp. 395-406

Florent Richy, Guilhem Pietri, Kimberly Moran, Emmanuelle Senior and Lydia Makaroff

Pre-Diagnosis Excess Acute Care Costs in Alzheimer’s Patients among a US Medicaid Population pp. 407-413

David Geldmacher, Noam Kirson, Howard Birnbaum, Sara Eapen, Evan Kantor, Alice Cummings and Vijay Joish

A Comparison of the EQ-5D-3L and ICECAP-O in an Older Post-Acute Patient Population Relative to the General Population pp. 415-425

Leah Couzner, Maria Crotty, Richard Norman and Julie Ratcliffe

Explaining the Health Costs Associated with Managing Intracranial Aneurysms in Italy pp. 427-435

Stefano Calciolari, Aleksandra Torbica and Rosanna Tarricone

Volume 11, issue 3, 2013

Resource-Use Measurement Based on Patient Recall: Issues and Challenges for Economic Evaluation pp. 155-161

Joanna Thorn, Joanna Coast, David Cohen, William Hollingworth, Martin Knapp, Sian Noble, Colin Ridyard, Sarah Wordsworth and Dyfrig Hughes

Patient Preferences Versus Physicians’ Judgement: Does it Make a Difference in Healthcare Decision Making? pp. 163-180

Axel Mühlbacher and Christin Juhnke

Cost Effectiveness of Fecal DNA Screening for Colorectal Cancer: A Systematic Review and Quality Appraisal of the Literature pp. 181-192

Mairead Skally, Paul Hanly and Linda Sharp

Time Costs Associated with Informal Care for Colorectal Cancer: An Investigation of the Impact of Alternative Valuation Methods pp. 193-203

Paul Hanly, Alan Céilleachair, Mairead Skally, Eamonn O’Leary, Anthony Staines, Kanika Kapur, Patricia Fitzpatrick and Linda Sharp

Multilevel Analysis of the Influence of Patients’ and General Practitioners’ Characteristics on Patented Versus Multiple-Sourced Statin Prescribing in France pp. 205-218

Sylvain Pichetti, Catherine Sermet, Brian Godman, Stephen Campbell and Lars Gustafsson

Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective pp. 219-236

Ronald Wielage, Megha Bansal, J. Andrews, Robert Klein and Michael Happich

Implications of a Data-Driven Approach to Treatment with Growth Hormone in Children with Growth Hormone Deficiency and Turner Syndrome pp. 237-249

Stefan Kaspers, Michael Ranke, Donald Han, Jane Loftus, Hartmut Wollmann, Anders Lindberg, Mathieu Roelants and Joris Kleintjens

Community-Acquired Pneumonia Episode Costs by Age and Risk in Commercially Insured US Adults Aged ≥50 Years pp. 251-258

Reiko Sato, Gabriel Gomez Rey, Stephanie Nelson and Brett Pinsky

A UK-Based Cost-Utility Analysis of Indacaterol, A Once-Daily Maintenance Bronchodilator for Patients with COPD, Using Real World Evidence on Resource Use pp. 259-274

David Price, Yumi Asukai, Jaithri Ananthapavan, Bill Malcolm, Amr Radwan and Ian Keyzor

Medicare Fee-for-Service Enrollees with Primary Acute Myeloid Leukemia: An Analysis of Treatment Patterns, Survival, and Healthcare Resource Utilization and Costs pp. 275-286

Juliana Meyers, Yanni Yu, James Kaye and Keith Davis

A Pilot Discrete Choice Experiment to Explore Preferences for EQ-5D-5L Health States pp. 287-298

Richard Norman, Paula Cronin and Rosalie Viney

Economic Burden of Non-Cystic Fibrosis Bronchiectasis in the First Year after Diagnosis from A US Health Plan Perspective pp. 299-304

Vijay Joish, Monica Spilsbury-Cantalupo, Elisabeth Operschall, Ba Luong and Susan Boklage

Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison pp. 305-305

Carlos Alatorre, Virginia Haynes, Douglas Faries, Himanshu Upadhyaya and Douglas Kelsey

Authors’ Reply to Alatorre et al.: “Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison” pp. 307-307

M. Erder, Jipan Xie, James Signorovitch, Kristina Chen, Paul Hodgkins, Mei Lu, Eric Wu and Vanja Sikirica

Erratum to: Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder pp. 309-309

M. Erder, Jipan Xie, James Signorovitch, Kristina Chen, Paul Hodgkins, Mei Lu, Eric Wu and Vanja Sikirica

Volume 11, issue 2, 2013

Model Performance Evaluation (Validation and Calibration) in Model-based Studies of Therapeutic Interventions for Cardiovascular Diseases pp. 85-93

Hossein Haji Ali Afzali, Jodi Gray and Jonathan Karnon

The Cost Effectiveness of Long-Acting/Extended-Release Antipsychotics for the Treatment of Schizophrenia pp. 95-106

Evanthia Achilla and Paul McCrone

Cost-Effectiveness Analysis of 3-D Computerized Tomography Colonography Versus Optical Colonoscopy for Imaging Symptomatic Gastroenterology Patients pp. 107-117

Manuel Gomes, Robert Aldridge, Peter Wylie, James Bell and Owen Epstein

Annual All-Cause Healthcare Costs Among Influenza Patients With and Without Influenza-Related Complications pp. 119-128

Sudeep Karve, Derek Misurski, Guillermo Herrera-Taracena and Keith Davis

Cost Effectiveness of Pegfilgrastim Versus Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Lymphoma and Myeloma pp. 129-138

Lionel Perrier, Anne Lefranc, David Pérol, Philippe Quittet, Aline Schmidt-Tanguy, Carole Siani, Christian Peretti, Bertrand Favier, Pierre Biron, Philippe Moreau, Jacques Bay, Séverine Lissandre, Fabrice Jardin, Daniel Espinouse and Catherine Sebban

Measuring the Loss of Consumer Choice in Mandatory Health Programmes Using Discrete Choice Experiments pp. 139-150

Bonny Parkinson, Stephen Goodall and Richard Norman

Is it Financially Efficient to Lose the Ring-Fenced Elective Orthopaedic Ward? pp. 151-154

J. Soler, Sanjiv Manjure and Yegappan Kalairajah

Volume 11, issue 1, 2013

Cost-Effectiveness Assessment of Orphan Drugs pp. 1-3

Steven Simoens, Eline Picavet, Marc Dooms, David Cassiman and Thomas Morel

Pipeline™ Embolization Device for the Treatment of Complex Intracranial Aneurysms pp. 5-13

Kathleen Withers, Grace Carolan-Rees and Megan Dale

The Economic Evaluation of Medical Devices pp. 15-26

Andreas Kirisits and W. Redekop

A Systematic Review of Economic Evaluations in Second and Later Lines of Therapy for the Treatment of Non-Small Cell Lung Cancer pp. 27-43

Anne Jäkel, Melanie Plested, Kuntal Dharamshi, Rakhee Modha, Sarah Bridge and Adam Johns

Lessons from Game Theory about Healthcare System Price Inflation pp. 45-51

Mark Agee and Zane Gates

Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH Model pp. 53-63

Phil McEwan, Ray Kim and Yong Yuan

Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal pp. 65-78

Elamin Elbasha, Jagpreet Chhatwal, Shannon Ferrante, Antoine El Khoury and Pedro Laires

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing pp. 79-82

Brian Godman and Lars Gustafsson

Authors’ Reply to Godman and Gustafsson: “A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing” pp. 83-84

Ulf Persson, Johanna Svensson and Billie Pettersson